title: Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.
authors.forename: R G
authors.initials: RG
authors.lastname: Piazza
authors.forename: V
authors.initials: V
authors.lastname: Magistroni
authors.forename: M
authors.initials: M
authors.lastname: Gasser
authors.forename: F
authors.initials: F
authors.lastname: Andreoni
authors.forename: A
authors.initials: A
authors.lastname: Galietta
authors.forename: L
authors.initials: L
authors.lastname: Scapozza
authors.forename: C
authors.initials: C
authors.lastname: Gambacorti-Passerini
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides; D019008:Drug Resistance, Neoplasm / Q000235:genetics*; D016044:Fusion Proteins, bcr-abl / Q000737:chemistry / Q000235:genetics*; D006801:Humans; D000068877:Imatinib Mesylate; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy / Q000235:genetics*; D008958:Models, Molecular; D009154:Mutation; D010879:Piperazines / Q000494:pharmacology / Q000627:therapeutic use*; D011743:Pyrimidines / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D016044:Fusion Proteins, bcr-abl